CNTA — Centessa Pharmaceuticals PLC ADR
NASDAQ · Healthcare · Biotechnology
Centessa Pharmaceuticals PLC ADR (CNTA) is a biotechnology company listed on NASDAQ. It is led by Mario Alberto Accardi Ph.D., based in 1 Ashley Road, Altrincham, United Kingdom, WA14 2DT, with about 129 employees. Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Latest reported CNTA revenue for 2025-09-30 was $0. Net income was -$54.9M. CNTA currently screens at market cap $6.15B.
Use this CNTA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CNTA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CNTA SEC filings page. Lician reads the product cache first so this HTML stays unique to Centessa Pharmaceuticals PLC ADR even when a live quote feed is slow.
About Centessa Pharmaceuticals PLC ADR
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
CNTA Key Statistics
Market Cap
$6.15B
EPS
-$2.06
Revenue
$0.00
Net Income
-$235.76M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-100.0%
Employees
129
CNTA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $6.85M | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$235.76M | -$151.09M | -$216.21M | -$381.07M |
| EPS (Diluted) | -$2.06 | -$1.57 | -$2.31 | -$5.07 |
Total Assets
$576.80M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$383.22M
Operating Cash Flow
-$142.06M
Free Cash Flow
$0.00
Centessa Pharmaceuticals PLC ADR Company Information
- CEO & Director
- Mario Alberto Accardi Ph.D.
- Headquarters
- 1 Ashley Road, Altrincham, United Kingdom, WA14 2DT
- Website
- centessa.com
- Phone
- 44 617 4685770
- IPO / Founded
- 2021-05-28
- Sector
- Healthcare
- Industry
- Biotechnology